SEC Form 4 · accession 0001144204-16-127730
IMMUNE PHARMACEUTICALS INC · IMNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel Gedeon Teper
Officer — CEO · Director · 10% Owner
Period of report
Oct 6, 2016
Accepted (ET)
Oct 11, 2016 · 6:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001208261
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 6, 2016 | M | 185,473 | $0.04 | A | 5,865,280 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock optionF1 | $0.04 | Oct 6, 2016 | M | 185,473 | D | — | Jul 8, 2022 | Common Stock | 185,473 | 185,473 | D |
Explanation of responses
- F1The option was granted on July 10, 2012 and vested on June 30, 2013.